You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

114 Results
Document
Feb 2018
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Aug 2020
Guidelines and Advice
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Curative
May 2019
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer
Oct 2023

Pages